Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

X
Trial Profile

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RLY-2608 (Primary) ; Fulvestrant
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ReDiscover
  • Sponsors Relay Therapeutics
  • Most Recent Events

    • 22 Feb 2024 According to a Relay Therapeutics media release, RLY-2608 plus fulvestrant data update in the second half of 2024. RLY-2608 plus fulvestrant plus ribociclib initial safety data in the second half of 2024.
    • 22 Feb 2024 According to a Relay Therapeutics media release, completed enrollment in initial RLY-2608 600mg plus fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg. Initiated RLY-2608 plus fulvestrant plus ribociclib triplet combination in PI3Kalpha-mutated HR+/HER2- metastatic breast cancer.
    • 02 Feb 2024 Study design discussed in 46th Annual San Antonio Breast Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top